Potential applications of magnetic particles to detect and treat Alzheimer's disease

被引:0
作者
Maria Antònia Busquets
Raimon Sabaté
Joan Estelrich
机构
[1] Universitat de Barcelona,Departament de Fisicoquímica, Facultat de Farmàcia
[2] Universitat de Barcelona,Institut de Nanociència i Nanotecnologia (IN2UB)
来源
Nanoscale Research Letters | / 9卷
关键词
Superparamagnetic iron oxide nanoparticles; Gadolinium; Magnetic resonance imaging; Amyloid; Bio-barcode assay;
D O I
暂无
中图分类号
学科分类号
摘要
Nanotechnology is an exciting and promising scientific discipline. At the nanoscale, a material displays novel physical properties that offer many new and beneficial products and applications. In particular, magnetic nanoparticles - a core/shell nanoparticle - present considerable diagnostic and therapeutic potentials, and superparamagnetic iron oxide nanoparticles (SPIONs) are considered promising theranostic tools. Alzheimer's disease (AD) is a neurodegenerative disorder that predominantly affects people over 65 years of age. The disease is characterized by the presence of extracellular plaques in the brain which are formed by interwoven fibrils composed of variants of the β-amyloid peptide. Medication can temporarily retard worsening of symptoms, but only in the first stages of the disease; early detection is thus of crucial importance. This minireview covers the progress made in research on the use of magnetic nanoparticles for ex vivo and/or in vivo detection and diagnosis of AD by means of magnetic resonance imaging (MRI), or to label peptides and fibrils. Of particular importance is the use of these nanoparticles to detect AD biomarkers in biological fluids. A description is given of the bio-barcode amplification assay using functionalized magnetic particles, as well as the use of such nanoparticles as a system for inhibiting or delaying the assembly of peptide monomers into oligomers and fibrils. Lastly, a brief overview is given of possible future lines of research in this.
引用
收藏
相关论文
共 276 条
[1]  
Harper JD(1997)Models of amyloid seeding in Alzheimer’s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins Annu Rev Biochem 66 385-407
[2]  
Lansbury PT(2001)Alzheimer β-amyloid peptides: structures of amyloid fibrils and alternate aggregation products Biopolymers 60 381-394
[3]  
Gorman PM(2002)Peptide aggregation in neurodegenerative disease Annu Rev Biomed Eng 4 155-174
[4]  
Chakrabartty A(2003)Unfolding the role of protein misfolding in neurodegenerative diseases Nature Rev Neurosci 4 49-60
[5]  
Murphy RM(1984)Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein Biochem Biophys Res Commun 120 885-890
[6]  
Soto C(1996)New clues to Alzheimer's disease: unraveling the roles of amyloid and tau Nat Med 2 850-852
[7]  
Glenner GG(2002)The amyloid hypothesis of Alzheimer’s disease: progress and problems of the road to therapeutics Science 297 353-356
[8]  
Wong CW(1999)Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons J Neurosci 19 8876-8884
[9]  
Yankner BA(2001)Targeting small Aβ oligomers: the solution to an Alzheimer’s disease conundrum? Trends Neurosci 24 219-224
[10]  
Hardy J(2002)The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease J Neurosci 22 1858-1867